Contacts

Individual shareholders Contacts: Toll free number :
(33) 800 075 876

USA Toll free number :
+1 888 516 3002
For other inquiries:
Please click on this link; Address :
174, avenue de France
75013 PARIS
FRANCE; Switchboard :
(33) 1 53 77 4000

Content :

Becoming a shareholder

You can become a sanofi-aventis shareholder by buying just one of our shares. Once you are a shareholder, you will enjoy a special relationship with us: by investing in our shares, you register a vote of confidence in our strategy, our management team, our business and our future.

We offer potential shareholders all the information they need to help them in their investment decision, both on this website and through other sources.

Our shares

Sanofi-aventis shares rank third in the CAC 40 index in terms of market capitalization. At December 31, 2007, our market capitalization was €86,025 million.

Variation in the Sanofi-aventis share price over the last years
	2002	2003	2004	2005	2006	2007
Dividends (paid out the following year)	0.84	1.02	1.20	1.52	1.75	2.07
Share price in euros
High	84.30	60.00	63.25	76.70	79.85	71.95
Low	49.78	41.50	49.42	56.40	64.85	56.20
Latest	58.25	59.70	58.80	74.00	69.95	62.98
Market capitalization at end December (in millions of euros)	42,660	43,751	82,990	103,696	95,092	86,025
Ranking in CAC 40 by market capitalization	3	6	2	2	3	3

Our shares are listed on Eurolist by Euronext Paris, compartment A, and on the New York Stock Exchange in the form of American Depositary Receipts (ADRs). Use the Stock Information pages on our website to track our share price in real time either in Paris or New York and to compare our performance to benchmark indices.

Key figures

Sanofi-aventis is one of the leaders of the world pharmaceutical industry. In 2007, net sales were up 2.8%* at €28,052 million, despite the genericization of two major products. Pharmaceuticals net sales increased 1.7%*, with our top 15 products progressing by 3.2%*. Vaccines net sales rose sharply by 14.5%*.
*on a comparable basis

2007 sanofi-aventis key figures
ValuesIn millions of euros	2007	As % of net sales
Net sales	28,052	100 %
Adjusted gross profit*	21,636	77.1 %
Research & Development expenses	(4,537)	(16.2 %)
Selling and general expenses	(7,554)	(26.9 %)
Adjusted operating income – current*	9,617	34.3 %
Adjusted net income*	7,110	25.3 %
Adjusted EPS* (in euros)	5.28	-
Adjusted EPS excluding selected items* (in euros)	5.17	-
Dividends (in euros)	2.07	-